E-cigarette Usage in UK Reaches Record High Levels

Aug.12.2024
E-cigarette Usage in UK Reaches Record High Levels
The e-cigarette use among UK adults has reached a record high, with 11% using them, totaling 5.6 million people.

According to a report from the Shropshire Star on August 12th, the use of e-cigarettes among adults in the UK has reached a record high. The latest data shows that 11% of UK adults use e-cigarettes, equating to 5.6 million people.


According to data from Action on Smoking and Health (ASH) in the UK, approximately 53% of e-cigarette users, which is equivalent to 3 million people, were previously traditional cigarette smokers. Currently, the proportion of people who use both traditional cigarettes and e-cigarettes has increased from 17% in 2021 to 32% in 2024, equivalent to 2.2 million people.


Ash's deputy chief executive Hazel Cheeseman said:


Smoking remains the biggest preventable killer in the UK, and e-cigarettes are one of the important tools to help smokers quit in order to achieve a smoke-free nation for both current and future generations.


Professor Sanjay Agrawal, Special Advisor on Tobacco Issues at the Royal College of Physicians and Consultant in Respiratory and Intensive Care Medicine at the University Hospitals of Leicester NHS Trust, added:


In the past few years, almost all of the patients I have encountered who have successfully quit smoking have done so by using e-cigarettes, without which they may have not been able to quit. E-cigarettes have been used by quit smoking services and the NHS to support smokers, but we can still more widely use this tool to help millions of people who are still smoking to quit.


According to reports, in July of this year, the Labour government restarted its plan to introduce the Tobacco and E-Cigarette Bill, which could gradually raise the age limit for purchasing tobacco and prevent anyone born after January 1, 2009 from legally purchasing tobacco. The bill could also impose restrictions on the flavors, packaging, and display of e-cigarettes.


Ms. Chisman emphasized that the proposed e-cigarette legislation should focus on preventing children from using e-cigarettes, rather than adults who are looking to quit smoking. She added:


In recent years, millions of people have successfully quit smoking by using e-cigarettes, extending their healthy lifespan and boosting national productivity. There is an urgent need for stricter regulations on e-cigarettes, but it is important that these regulations target teenage e-cigarette use specifically, without hindering their use as a smoking cessation aid.


Henry Gregg, Director of External Affairs for the British Lung Foundation, said:


Quitting smoking can be very difficult, and it is great to see that many smokers are finding e-cigarettes to be a very effective tool for quitting. However, in order to help more smokers quit, the government must increase investment in local smoking cessation services. In recent years, these services have faced significant cuts, but they have excelled in supporting people to quit smoking permanently and address the deadly consequences of smoking.


According to a survey, half of smokers believe that e-cigarettes are as harmful as traditional cigarettes, and 60% of non-e-cigarette users who smoke also share the same view.


A spokesperson for the UK Department of Health and Social Care stated:


Although e-cigarettes can be an effective tool for quitting smoking, health advice clearly states that non-smoking children and adults should never use e-cigarettes. The upcoming Tobacco and E-Cigarette Act will protect future generations from the harm of tobacco and nicotine, saving thousands of lives. By establishing a healthier society, it will also contribute to building a healthier economy.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
A consumer survey by Japanese heated tobacco information platform RELAZO found that rising tobacco prices and planned heated tobacco tax changes may influence smoking decisions among Japanese consumers. The survey covered 49,879 men and women aged 20 to 69 nationwide. It found that around 40% of respondents cumulatively indicated they may consider quitting when a pack reaches ¥600 (approximately US$4.1), while nearly 90% expressed potential quitting intentions at a ¥1,000 (approximately US$6.8) price level. The survey also found significant differences by income level, with lower-income respondents showing greater sensitivity to price increases.
Jul.24
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11